Compare · LGND vs VKTX
LGND vs VKTX
Side-by-side comparison of Ligand Pharmaceuticals Incorporated (LGND) and Viking Therapeutics Inc. (VKTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LGND and VKTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LGND is the larger of the two at $5.62B, about 1.4x VKTX ($3.99B).
- LGND has been more active in the news (8 items in the past 4 weeks vs 2 for VKTX).
- VKTX has more recent analyst coverage (23 ratings vs 11 for LGND).
- Company
- Ligand Pharmaceuticals Incorporated
- Viking Therapeutics Inc.
- Price
- $281.87+0.46%
- $34.17+2.89%
- Market cap
- $5.62B
- $3.99B
- 1M return
- -
- -1.98%
- 1Y return
- -
- +31.12%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 2
- Recent ratings
- 11
- 23
Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Viking Therapeutics Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Latest LGND
- Chief Financial Officer Espinoza Octavio exercised 31,641 shares at a strike of $56.91 and sold $9,241,229 worth of shares (31,641 units at $292.06) as part of a pre-agreed trading plan (SEC Form 4)
- Director Haas Jason exercised 6,138 shares at a strike of $51.56 and sold $2,090,062 worth of shares (7,138 units at $292.81), decreasing direct ownership by 20% to 3,981 units (SEC Form 4)
- Leerink Partners initiated coverage on Ligand Pharma
- Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ligand Reports Second Quarter 2026 Financial Results
- CLO & Secretary Reardon Andrew sold $1,444,951 worth of shares (5,000 units at $288.99) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $52.27 (SEC Form 4)
- Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
- SEC Form S-8 filed by Ligand Pharmaceuticals Incorporated
Latest VKTX
- Director Kelly-Gemmell Dorothy Elizabeth was granted 6,333 shares (SEC Form 4)
- SEC Form 3 filed by new insider Kelly-Gemmell Dorothy Elizabeth
- SEC Form S-3ASR filed by Viking Therapeutics Inc.
- President & CEO Lian Brian sold $4,947,888 worth of shares (148,517 units at $33.32) and was granted 221,667 shares, increasing direct ownership by 3% to 2,572,441 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Zante Greg was granted 31,667 shares and sold $710,141 worth of shares (21,217 units at $33.47), increasing direct ownership by 5% to 212,204 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Mancini Marianna was granted 31,667 shares and sold $609,636 worth of shares (18,217 units at $33.47), increasing direct ownership by 3% to 422,760 units (SEC Form 4) (for withholding tax)
- SEC Form 10-Q filed by Viking Therapeutics Inc.
- Viking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 144 filed by Viking Therapeutics Inc.